Myeloma Guide: Information for Patients and Caregivers

Revised 2023
A six-word narrative about living with blood cancer from patients in our LLS Community

Stay strong and keep moving forward. Find the positive in every day. Be your own best patient advocate. Changed my life for the better. Accept, learn and focus on present. Learning to live a different life. Sudden and life changing—be positive. Waiting, worrying, anxiousness/happy I’m alive! Embrace a new normal each day. 5 years, 41 infusions, constant fatigue. Patience, positive attitude, hope and faith. Test to test, I will survive! Treatment, fatigue, treatment, fatigue and survival. Love life, live better every day. I don’t look back only forward. So far, so good, live life. Meditation, mindfulness, wellness, faith, and optimism. Finding joy while living with uncertainty. Watch, wait, treat, regroup, rest, re-energize. Blessed to be doing so well! Eye opening needed learning and healing. Feel great: uncertain travel plans annoying. Renewed faith, meditation, diet, mindfulness, gratitude. Watchful waiting can be watchful worrying. Scary, expensive, grateful, blessings, hope, faith. Thank god for stem cell transplants! Do not know what to expect. Extraordinarily grateful, I love my life. Diagnosed; frightened; tested; treating; waiting; hoping. I’m more generous, impatient less often. Embrace your treatment day after day. Live today, accept tomorrow, forget yesterday. Strength you never realized you had. Challenging to our hearts and minds. Life is what we make it. Live life in a beautiful way.

Discover what thousands already have at

www.LLS.org/Community

Join our online social network for people who are living with or supporting someone who has a blood cancer. Members will find:

- Thousands of patients and caregivers sharing experiences and information, with support from knowledgeable staff
- Accurate and cutting-edge disease updates
- The opportunity to participate in surveys that will help improve care
Support for this publication provided by Bristol Myers Squibb; Genentech, A Member of The Roche Group; GSK plc; Karyopharm Therapeutics; Sanofi US.

This publication is designed to provide accurate and authoritative information about the subject matter covered. It is distributed as a public service by The Leukemia & Lymphoma Society (LLS), with the understanding that LLS is not engaged in rendering medical or other professional services. LLS carefully reviews content for accuracy and confirms that all diagnostic and therapeutic options are presented in a fair and balanced manner without particular bias to any one option.
INTRODUCTION

Myeloma is a type of cancer that forms in a plasma cell. Plasma cells are white blood cells found in the bone marrow.

Myeloma treatment advances have led to a better overall survival rate. This allows many patients to maintain a good quality of life for years.

- About 34,470 people in the United States were expected to be diagnosed with myeloma in 2022.
- About 147,663 people in the United States are living with or in remission from myeloma.

In recent years, new therapies have been approved for myeloma, and other new treatments are being studied in clinical trials. Progress toward a cure is underway.

Visit www.LLS.org/booklets to view, download or order all LLS free publications mentioned in this booklet.

WANT MORE INFORMATION?

You can view, print or order the free LLS booklet Myeloma at www.LLS.org/booklets, or contact our Information Specialists for a copy.

New treatments may have been approved since this booklet was printed. Check www.LLS.org/DrugUpdates or call (800) 955-4572.

Feedback. Visit www.LLS.org/PublicationFeedback to make suggestions about this booklet.
Overview of This Section

- Blood cells begin as stem cells, which are made in bone marrow, inside the bones. Stem cells normally develop into healthy red blood cells, white blood cells or platelets, and then leave the bone marrow and enter the bloodstream.
- Plasma cells are a type of white blood cell that make antibodies to help the body fight infection.
- Meloma starts with a change (mutation) to a single plasma cell.
- Myeloma is diagnosed with bone marrow tests, blood and urine tests, and imaging tests.

About Bone Marrow, Blood and Blood Cells

The general descriptions below may help you understand the information in the rest of this Guide.

**Bone marrow** is the spongy tissue located inside the center of most bones. This is where blood cells are made.

**Blood cells** begin as stem cells in the bone marrow. Stem cells grow and mature into different type of cells: red blood cells, white blood cells and platelets. After the cells have matured, the red blood cells, white blood cells and platelets enter the bloodstream.

**Red blood cells** carry oxygen around the body. When the number of red blood cells is below normal, a condition called **anemia** usually develops. Anemia may make you feel tired or short of breath. It may make your skin look pale.
**White blood cells** fight infection in the body. There are five types of white blood cells, which are usually categorized into two groups, lymphocytes and germ-eating cells:

- Lymphocytes are infection-fighting cells and include:
  1. B cells
  2. T cells
  3. NK (natural killer) cells

- Germ-eating cells kill and ingest bacteria and include:
  4. Neutrophils
  5. Monocytes

**Platelets** help stop bleeding by clumping together (**clotting**) at the site of an injury.

**Plasma** is the light yellow liquid that is part of the blood. Although mostly water, plasma also has some vitamins, minerals, proteins, hormones and other natural chemicals in it. Blood plasma is not the same as plasma cells, which are a type of white blood cell.
Normal Blood Cell Count Fast Facts

The ranges of blood cell counts below are for adults. They may be a little different from lab to lab and for children and teens.

**Red blood cell (RBC) count**
- Men: 4.5 to 6 million red cells per microliter of blood
- Women: 4 to 5 million red cells per microliter of blood

**Hematocrit (the part of the blood made up of red cells)**
- Men: 42% to 50%
- Women: 36% to 45%

**Hemoglobin (amount of the red cell pigment that carries oxygen)**
- Men: 14 to 17 grams per 100 milliliters of blood
- Women: 12 to 15 grams per 100 milliliters of blood

**Platelet count (PLAT C)**
- 150,000 to 450,000 platelets per microliter of blood

**White blood cell (WBC) count**
- 4,500 to 11,000 white cells per microliter of blood

**Differential (also called diff)**
- Shows the part of the blood made up of different types of white cells
- Counts the types of white cells (neutrophils, lymphocytes, monocytes, eosinophils and basophils)
  - Normal adult white blood cell count: 60% neutrophils, 30% lymphocytes, 5% monocytes, 4% eosinophils and less than 1% basophils in the blood
About Myeloma

Myeloma is a cancer of plasma cells, a type of white blood cell. Healthy plasma cells are part of the immune system—they make proteins called antibodies that help fight infection.

Myeloma begins in the bone marrow. It starts with a change (mutation) to a single plasma B cell. In the bone marrow, normal immature B cells develop into normal plasma cells. But in myeloma, a change in one plasma B cell can cause it to become a myeloma cell instead of a normal plasma cell. This mutated myeloma cell multiplies into many myeloma cells. As the myeloma cells multiply in the bone marrow, they crowd out the other types of healthy cells: red blood cells, white blood cells and platelets. As a result, the number of red blood cells, white blood cells and platelets may become lower than normal.

Instead of producing helpful antibodies that fight infection, the myeloma cells produce abnormal antibodies that are not needed by the body and do not help fight infection. These abnormal antibodies can also damage the kidneys.

While the myeloma cells are most commonly found in the bone marrow, they may build up in other parts of the body as cell masses. These collections of myeloma cell masses are known as plasmacytomas. They most commonly occur in the bones, skin, muscles or lungs. If the myeloma cells form a single cell mass, it is called a solitary plasmacytoma.

Myeloma that is found in several areas of the body is called multiple myeloma. Most patients with myeloma have multiple myeloma.

The term smoldering myeloma refers to a slow-growing type of myeloma. Usually, there are no symptoms at diagnosis and patients do not need treatment right away.

Causes and Risk Factors of Myeloma. Myeloma starts with a change to a single cell in the bone marrow. Doctors do not know why some people get myeloma and others do not. There is no way to prevent myeloma. You cannot catch myeloma from someone else.
While the cause of myeloma is unknown, the risk of developing myeloma may be increased by certain factors, such as:

- **Age**—Most people who develop myeloma are older than 50 years.
- **Sex**—More males than females develop myeloma.
- **Race**—Blacks are more likely to develop myeloma than whites.
- **Environmental factors**—Some studies are investigating a link between the development of myeloma and exposure to radiation or certain kinds of chemicals, such as pesticides, fertilizers and Agent Orange.
- **Obesity**—Research suggests that obese people have a higher incidence of myeloma.
- **Firefighting**—Some studies indicate that firefighters are at a higher risk for many types of cancer, including myeloma.
- **Presence of chronic immunodeficiency**
- **Presence of known inflammatory diseases or conditions (for example, cardiovascular disease or type II diabetes)**

**WANT MORE INFORMATION?**

You can view, print or order the free LLS awareness postcard *Firefighters and Cancer Risk* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for copies. For information on the World Trade Center (WTC) Health Program, see page 45.

**Signs and Symptoms.** Healthy people often have a sign or a symptom when they get an illness or a disease.

A **sign** is a change in the body that the doctor sees in an exam or a test.

A **symptom** is a change in the body that the patient can see or feel.

In the early stages of myeloma, some people have no signs or symptoms of the disease. These people may find out they have myeloma after a regular medical checkup that shows changes in their blood and/or urine.
When people do have signs and/or symptoms of myeloma, the most common include:

- Fatigue, severe tiredness
- Bone pain or bone fractures with no known cause

Doctors sometimes use the acronym **CRAB** to describe signs of myeloma. The letters stand for:

**C**—Calcium elevation: high levels of calcium in the blood, also known as *hypercalcemia*

**R**—Renal failure: poor function of the kidneys that may be caused by deposits of myeloma protein in the kidneys

**A**—Anemia: low red blood cell count

**B**—Bone abnormalities called “lesions”

Treatment is usually recommended for patients who have one or more of the four signs listed above.

**Diagnosis**

It is important for patients to receive the right diagnosis. When a person has signs and/or symptoms of myeloma, the doctor does tests to find out the cause. Myeloma is diagnosed with blood and urine tests, bone marrow tests, and imaging tests.

**Here are some questions you may want to ask your healthcare team.** See pages 53-58 for a full list of questions.

1. What kind of testing will be done to diagnose my disease and to monitor my treatment?
2. How long does it take to get the results?
3. How will the results be communicated to me?
4. How often will testing be needed?
5. Where will the testing be done?
**Blood and Urine Tests.** Tests are done to see if a protein called “M protein” is in the patient’s blood and urine. M protein is short for *monoclonal protein*, an antibody found in large amounts in the blood or urine of people with myeloma. Measuring the amount of M protein is one way to tell the severity (in cancer, this is called the “stage”) of the myeloma.

Other proteins, called “light chains” (also known as Bence Jones protein), may be found in the myeloma patient’s urine. A special test to check for light chains is called a **serum free light chain test**.

**Bone Marrow Tests.** People with myeloma have too many plasma cells in their bone marrow. Bone marrow tests are done to find out the percentage of plasma cells in the bone marrow.

**Visit** [www.LLS.org/3D](http://www.LLS.org/3D) and click on "Bone Marrow Biopsy and Aspiration" to view an interactive 3D image which will help you visualize and better understand the bone marrow aspiration and biopsy procedures.

---

**How Are the Blood and Bone Marrow Tests Done?**

**Blood Test**—A small amount of blood is taken from the patient’s arm with a needle. The blood is collected in tubes and sent to a lab.

**Bone Marrow Aspiration**—The removal of a sample of fluid with cells from the bone marrow.

**Bone Marrow Biopsy**—A very small amount of bone filled with marrow cells is taken from the body.

Both bone marrow tests are done with special needles. Some patients are awake for the procedure. Others are given drugs that help them relax or sleep. Patients then get medication to numb the part of the body from which the samples are taken. The sample of cells is usually taken from the patient’s hip bone.

Blood and marrow tests may be done in the doctor’s office or in a hospital. Bone marrow aspiration and biopsy are almost always done at the same visit.
Bone Marrow Aspiration and Biopsy

Bone Marrow Aspiration samples fluid and cells
Common site where sample is taken

Bone Marrow Biopsy samples bone and marrow

Needles
Skin and fat
Compact bone

Figure 1. Left: The place on the back of the patient’s hip bone where a bone marrow aspiration or biopsy is done. Right: One needle goes into bone marrow to get a liquid sample for aspiration (left) and the other needle goes inside the bone for a bone biopsy (right). The needle for aspiration is thinner than the one for biopsy.

Cytogenetic Analysis. Fluorescence in situ hybridization (FISH) is a type of laboratory test that is used to see if there are changes to the chromosomes of the myeloma cells taken from the bone marrow. Chromosomes are the parts of a cell that contain genetic information. Normal human cells contain 23 pairs of chromosomes, each of which are a certain size, shape and structure. In some cases of myeloma, the chromosomes of the myeloma cells have abnormal changes. The results of the cytogenetic analysis test help your doctor plan your treatment.

Molecular Tests. Molecular tests are very sensitive DNA tests that check for specific gene mutations in the myeloma cells. Results from these tests may be used for treatment planning. Next-generation sequencing is a test that may be helpful to better predict outcomes. It may also help develop new and improved targeted therapies. This is currently being done only in research but may soon be used in routine practice.
**Imaging Tests.** Imaging tests make pictures (images) of the inside of the body. They are a very important part of the diagnosis, staging and management of myeloma. These include:

- **Bone/skeletal survey.** X-rays of all the bones in the body are taken and examined to identify areas of decreased bone density, bone lesions, holes or breaks in any bones, or thinning of the bones.

- **Magnetic resonance imaging (MRI).** This imaging test is done in select cases. It uses a powerful magnet to detect abnormalities in the bone marrow.

- **Positron emission tomography imaging and computed tomography (PET-CT) scan.** A PET/CT scanner combines the techniques of both PET and CT in one machine. It provides a more detailed picture of where the cancer is located in the body than either test alone. PET-CT is the only imaging test used to evaluate treatment response.

---

**WANT MORE INFORMATION?**

You can view, print or order the free LLS booklet *Myeloma* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for a copy.

---

**Tracking Your Myeloma Tests**

These tips may help you save time and learn more about your health.

- Ask your doctor why certain tests are being done and what to expect.
- Discuss your test results with your doctor.
- Ask for and keep copies of lab reports in a file folder or binder. Organize reports by date.
- Find out if and when follow-up tests are needed.
- Mark upcoming appointments on your calendar.
PART 2  TREATING MYELOMA

Overview of This Section

- People with myeloma should choose a doctor who is a specialist in both blood diseases and cancer. This doctor is called a hematologist-oncologist.
- Ask questions about your treatment choices and do not be afraid to be involved in making decisions about your own care. See the Treatment and Follow-Up Care Question Guides on pages 55-58.
- For most people with myeloma, treatment begins with systemic drug therapy (meaning treatment travels through the bloodstream to kill the cancer cells).
- Many myeloma drugs are taken orally (by mouth). It is important for patients to take these drugs on the right day at the right time.
- It is very important to measure your response to treatment. The results help your doctor determine if your myeloma is well-controlled.

Finding the Right Doctor

Choose a doctor who specializes in treating myeloma and knows about the most up-to-date treatments. This type of specialist is called a hematologist-oncologist. A hematologist is a doctor who has special training in disorders of the blood.

An oncologist is a doctor who has special training in cancer. A hematologist-oncologist has special training in both diagnosing and treating blood cancers.

WANT MORE INFORMATION?

You can view, print or order the free LLS publication Understanding Lab and Imaging Tests at www.LLS.org/booklets, or contact our Information Specialists for a copy.
Your local cancer specialist may work with a hematologist-oncologist. Always check to see if the doctor’s affiliated hospital is covered under your health insurance plan.

**How to Find a Myeloma Specialist**

- Ask your primary care doctor for a recommendation.
- Contact your community cancer center.
- Reach out to doctor and/or health insurance plan referral services.
- Call an LLS Information Specialist at (800) 955-4572.
- Use online doctor-finder resources, such as
  - The American Medical Association’s (AMA) “DoctorFinder” online at https://doctorfinder.ama-assn.org/doctorfinder/
  - The American Society of Hematology’s (ASH) “Find a Hematologist” online at https://www.hematology.org/Patients/FAH.aspx

When you meet with the specialist, ask questions to get a better idea of the doctor’s experience and to understand how the office works. Some sample questions are below. See pages 53-58 for a full list of questions.

1. How many patients have you treated who have myeloma?
2. What problems or symptoms should be reported to the nurse or doctor right away?
3. Is there a release form available so my family/caregiver can be given medical information?

Make sure you feel comfortable interacting with the doctor and the rest of the staff. You will be spending a lot of time speaking with this staff and others at this treatment center.

**WANT MORE INFORMATION?**

You can view, print or order the free LLS fact sheet *Choosing a Blood Cancer Specialist or Treatment Center* at www.LLS.org/booklets, or contact our Information Specialists for a copy.
Ask Your Doctor

Talk with the doctor and ask questions about how they plan to treat your myeloma. This will help you become involved in making decisions about your care.

When you meet with your doctor

- Ask questions. Below are a few questions to ask. See pages 53-58 at the end of this Guide for a full list of questions. Visit www.LLS.org/WhatToAsk to find our other healthcare question guides.
  - What are my treatment choices?
  - Are there any clinical trials that I can join?
  - When do you think treatment should begin?
  - How long will treatment last?
- Take notes. It may be helpful to write down the answers to your questions and review them later.
- Audio record information from the doctor and then listen to the recording later. Ask the doctor and staff if recording is okay (cell phones have a “record” function; ask someone how to use it if you are not sure).
- Bring a caregiver, friend or family member who can listen to the doctor along with you, and who can take notes and offer support.
- Make sure you understand what the doctor is saying. If you do not understand, ask the doctor to explain it again.

If you need more information or are not sure about your treatment choices, consider getting another opinion (a second opinion) from a different qualified doctor. If you are unsure or feel uncomfortable about how to tell your doctor you are getting a second opinion, call one of our Information Specialists at (800) 955-4572 to discuss a way that makes you comfortable. You may also want to check with your insurance to ensure that a second opinion is covered.
Goals of Treatment

While there is no cure for myeloma, new treatments have improved patient quality of life and survival rates. The goals of myeloma treatment are to:

- Slow the growth of myeloma cells
- Reduce symptoms such as bone pain and fatigue
- Provide long periods of remission (when there are no signs of myeloma and/or the myeloma is not causing health problems)
- Lengthen survival while preserving quality of life.

Treatment Staging and Planning

The treatment plan for a patient depends on:

- The type and stage of myeloma
- The patient’s age
- The patient’s overall health

Staging. Once doctors diagnose cancer, they need to know how much cancer is in the body and where it is located. This process is called staging. Figuring out the stage of the cancer helps doctors determine how best to treat it.

Myeloma has three stages numbered from 1 to 3. Often doctors write the stage down in Roman numerals. You may see stage 1 written as Stage I, stage 2 written as Stage II and stage 3 written as Stage III. Knowing the stage can help the healthcare team predict a patient's prognosis (likely outcome of the disease). Doctors use bone marrow exams and lab and imaging tests to stage myeloma. These tests look at:

- Blood counts of red blood cells, white blood cells and platelets, which may be lower than normal
- The amount of M protein found in the blood and urine (M protein is made by myeloma cells)
- The calcium level in the blood, which may be higher than normal
- The beta₂ microglobulin level in the blood, which may be higher than normal
The albumin level in the blood, which may be lower than normal
- The bones, to see if there are any bone lesions
- The presence of high-risk cytogenetic (chromosome) abnormalities in the myeloma cells
- The lactate dehydrogenase level, which may be higher than normal

There are two staging systems. One is called the Durie-Salmon Staging System and the other is called the Revised International Staging System (ISS) for Multiple Myeloma.

**Treatment Planning.** Once you are diagnosed with myeloma, your healthcare team will customize your treatment approach based on a number of factors including:

- The stage of your myeloma
- The characteristics of your myeloma, such as the presence of chromosomal abnormalities
- The rate of disease progression—whether the cancer continues to grow or spread
- The presence of other conditions such as heart or kidney disease, diabetes or neuropathy (a nerve problem that causes pain, numbness, or tingling, usually in the hands or feet)
- Your age
- Your overall health

Patients are advised to consult a doctor who specializes in myeloma treatment to discuss the most appropriate treatment option for their diagnosis. Most treatment plans include a combination of different therapies.
About Myeloma Treatments

New treatments may have been approved since this booklet was printed. Check www.LLS.org/DrugUpdates or call (800) 955-4572.

Before you begin treatment, you and your healthcare team will discuss your treatment options. One option may be a clinical trial. Like all treatment options, clinical trials have possible risks and benefits. You can take an active role in making treatment decisions by considering all of your options, including clinical trials.

There are a number of treatments for myeloma. These include:

- Combination drug therapy
- High-dose chemotherapy followed by stem cell transplantation
- Immune cellular therapy (for example, chimeric antigen receptor [CAR] T-cell therapy)
- Radiation therapy for patients with localized disease (for example, a solitary plasmacytoma)
- New and emerging drug therapies (given in clinical trials, see pages 33-34)

A patient may receive drugs that are different from those described in this Guide. These drugs may still be considered proper treatment.

Speak to your healthcare team to find out what treatment is best for you.

Our Information Specialists can help you plan questions about treatment to ask your doctor.

Here are some questions you may want to ask your healthcare team. See pages 53-58 for full list of questions.

1. What stage is my cancer?
2. What are my treatment options, including treatments in clinical trials?
3. What is the goal of treatment?
4. What are the benefits and risks of these treatments?

5. Is any one treatment recommended over others?

For patients who have myeloma that grows slowly, an approach called “watch and wait” may be a better option than early treatment. In the watch-and-wait approach, treatment is delayed until there are signs that the disease is progressing. Frequent and careful observation by a doctor is required so that treatment can begin when the disease starts advancing. Patients with active myeloma, however, need immediate treatment.

Some patients will need supportive (palliative) care to address some symptoms and complications of myeloma such as anemia, high blood calcium levels, infection and bone damage (see Complications, Side Effects and Follow-Up Care on pages 35-41).

Drugs Used to Treat Myeloma. Systemic drug therapy (meaning treatment that travels through the bloodstream to kill myeloma cells) is the main treatment for active myeloma. The initial therapy for myeloma usually includes a combination of targeted agents (these work by targeting specific types of cancer cells) and/or standard chemotherapy. See Some Drugs Used in Myeloma Treatment on pages 19-26 and Some Drug Combinations for Myeloma Treatment on pages 27-28. This therapy is often followed by stem cell transplantation in patients who are eligible for this procedure. (See Stem Cell Transplantation on pages 28-30.)

For transplant candidates, drug treatment begins with a combination of agents that do not cause bone marrow damage. For example:

- **Bortezomib (Velcade®), lenalidomide (Revlimid®) and dexamethasone** (a combination known as VRD).
- **Bortezomib, cyclophosphamide (Cytoxan®) and dexamethasone** (a combination known as VCD or CyBorD), or
- Other combinations, such as the addition of **daratumumab (Darzalex®)** to the above combinations.

Note that long-term treatment with lenalidomide may decrease stem cell production. So for transplant candidates, stem cell collection is often performed after three to six cycles once a good treatment response has been achieved.
# Some Drugs Used in Myeloma Treatment

<table>
<thead>
<tr>
<th>Drug Name Administration</th>
<th>FDA-Approved Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Proteasome Inhibitors (PIs)</strong></td>
<td></td>
</tr>
</tbody>
</table>
| **Bortezomib (Velcade®)** Intravenous (IV) or subcutaneous (sub-Q or SC) | ☐ Approved to treat myeloma  
☐ Bortezomib re-treatment may be considered for patients with myeloma who had previously responded to treatment with bortezomib and who have relapsed at least six months after completing prior bortezomib treatment. |
| **Carfilzomib (Kyprolis®)** Intravenous (IV) | ☐ Approved for the treatment of patients with relapsed or refractory myeloma who have received one to three prior therapies, in combination with  
☐ Lenalidomide and dexamethasone; or  
☐ Dexamethasone; or  
☐ Daratumumab (Darzalex®) and dexamethasone  
☐ Daratumumab and hyaluronidase-fihj (Darzalex Faspro®) and dexamethasone; or  
☐ Isatuximab-irfc (Sarclisa®) and dexamethasone.  
☐ Approved as a single agent for the treatment of patients with relapsed or refractory myeloma who have received at least one or more prior therapies |
### Some Drugs Used in Myeloma Treatment *(continued)*

<table>
<thead>
<tr>
<th>Drug Name/Administration</th>
<th>FDA-Approved Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ixazomib (Ninlaro®)</strong></td>
<td>Approved for use in combination with lenalidomide and dexamethasone for the treatment of myeloma patients who have received at least one prior therapy</td>
</tr>
<tr>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td><strong>Immunomodulatory Drugs (IMiDs)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Lenalidomide (Revlimid®)</strong></td>
<td>Approved for the treatment of adult myeloma patients:</td>
</tr>
<tr>
<td>Oral</td>
<td>In combination with dexamethasone</td>
</tr>
<tr>
<td></td>
<td>To use as maintenance therapy following autologous stem cell transplant</td>
</tr>
<tr>
<td><strong>Pomalidomide (Pomalyst®)</strong></td>
<td>Approved for use in combination with dexamethasone for the treatment of adult myeloma patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression either on or within 60 days of completion of the last therapy</td>
</tr>
<tr>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td><strong>Thalidomide (Thalomid®)</strong></td>
<td>Approved for newly diagnosed adult myeloma patients for use in combination with dexamethasone</td>
</tr>
<tr>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>Monoclonal Antibodies</td>
<td>Approved for adult myeloma patients:</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------</td>
</tr>
</tbody>
</table>
| Elotuzumab (Empliciti®) Intravenous (IV) | ○ In combination with lenalidomide and dexamethasone in patients who have received one to three prior therapies  
○ In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor |
| Daratumumab (Darzalex®) Intravenous (IV) | ○ In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory myeloma who have received at least one prior therapy  
○ In combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant  
○ In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant  
○ In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy  
○ In combination with carfilzomib and dexamethasone in patients who have received one to three prior therapies (continued on page 22) |
<table>
<thead>
<tr>
<th>Drug Name Administration</th>
<th>FDA-Approved Indications</th>
</tr>
</thead>
</table>
| **Daratumumab (Darzalex®) (continued)** | ● In combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor  
● As monotherapy, in patients who have received at least three prior therapies including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to a PI and an immunomodulatory agent |
| **Daratumumab and hyaluronidase-fihj (Darzalex Faspro®) Subcutaneous (Sub-Q or SC)** | Approved for adult myeloma patients:  
● In combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant  
● In combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory myeloma who have received at least one prior therapy  
● In combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant  
● In combination with bortezomib and dexamethasone in patients who have received at least one prior therapy (continued on page 23) |
**Daratumumab and hyaluronidase-fihj (Darzalex Faspro®) (continued)**

- In combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior therapies
- As monotherapy, in patients who have received at least three prior therapies including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double refractory to both a PI and an immunomodulatory agent
- In combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide and a proteasome inhibitor

**NOTE:** Daratumumab may interfere with blood type test results for up to 6 months after your final dose. Be sure to notify the blood bank at all treatment centers if patients have received this medication, in case a blood transfusion is needed.

<table>
<thead>
<tr>
<th>Isatuximab-irfc (Sarclisa®) Intravenous (IV)</th>
<th>Approved for adult myeloma patients:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>○ In combination with pomalidomide and dexamethasone, for patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor</td>
</tr>
<tr>
<td></td>
<td>○ In combination with carfilzomib and dexamethasone, for patients with relapsed or refractory myeloma who have received 1 to 3 prior therapies</td>
</tr>
</tbody>
</table>
## Some Drugs Used in Myeloma Treatment (continued)

<table>
<thead>
<tr>
<th>Drug Name &amp; Administration</th>
<th>FDA-Approved Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bone-Modifying Agent</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Denosumab (Xgeva®)</strong></td>
<td>Approved for myeloma patients for the prevention of skeletal-related (bone) problems</td>
</tr>
<tr>
<td>Subcutaneous (sub-Q or SC)</td>
<td></td>
</tr>
<tr>
<td><strong>Alkylating Agents (DNA-Damaging Drugs)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Melphalan hydrochloride (Evomela®)</strong></td>
<td>Approved for the treatment of myeloma patients for use as a high-dose conditioning treatment prior to hematopoietic progenitor (stem) cell transplantation</td>
</tr>
<tr>
<td>Intravenous (IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Carmustine (BiCNU®)</strong></td>
<td>Approved to treat myeloma in combination with prednisone</td>
</tr>
<tr>
<td>Intravenous (IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Cyclophosphamide (Cytoxan®)</strong></td>
<td>Approved to be used alone or in combination with other medications to treat myeloma</td>
</tr>
<tr>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>Intravenous (IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Melphalan (Alkeran®)</strong></td>
<td>Approved to treat myeloma</td>
</tr>
<tr>
<td>Oral</td>
<td></td>
</tr>
<tr>
<td>Intravenous (IV)</td>
<td></td>
</tr>
<tr>
<td><strong>Selective Inhibitor of Nuclear Export (SINE)</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Selinexor (Xpovio®)</strong></td>
<td>Approved for adult myeloma patients:</td>
</tr>
<tr>
<td>Oral</td>
<td>In combination with bortezomib and dexamethasone for patients who have received at least one prior therapy</td>
</tr>
<tr>
<td>(continued on page 25)</td>
<td></td>
</tr>
<tr>
<td><strong>Selinexor (Xpovio®)</strong> <em>(continued)</em></td>
<td>In combination with dexamethasone for patients with relapsed or refractory myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td><strong>Chimeric Antigen Receptor (CAR) T-Cell Therapy</strong></td>
<td><strong>Idecabtagene vilcencel (Abecma®)</strong> Intravenous (IV)  Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody  <strong>Ciltacabtagene autoleucel (Carvykti™)</strong> Intravenous (IV)  Approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody  <strong>Bispecific B-cell maturation antigen (BCMA)</strong>  <strong>Teclistamab-cqyv (Tecvayli™)</strong> Subcutaneous (sub-Q or SC)  Approved for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody</td>
</tr>
</tbody>
</table>
### Some Drugs Used in Myeloma Treatment (continued)

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Administration</th>
<th>FDA-Approved Indications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bisphosphonates</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pamidronate (Aredia®) and</td>
<td>Intravenous (IV)</td>
<td>Two drugs that alleviate the effects of bone disease by decreasing the pain, likelihood</td>
</tr>
<tr>
<td>zoledronic acid (Zometa®)</td>
<td></td>
<td>of bone fractures and high blood calcium levels associated with bone destruction</td>
</tr>
<tr>
<td><strong>Corticosteroid</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dexamethasone</td>
<td>Oral Intravenous (IV)</td>
<td>Used to treat myeloma</td>
</tr>
<tr>
<td>Prednisone</td>
<td>Oral</td>
<td>Used to treat myeloma</td>
</tr>
<tr>
<td><strong>Antitumor Antibiotics</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liposomal doxorubicin (Doxil®)</td>
<td>Intravenous (IV)</td>
<td>Approved in combination with bortezomib in myeloma patients who have not previously</td>
</tr>
<tr>
<td></td>
<td></td>
<td>received bortezomib and have received at least one prior therapy</td>
</tr>
<tr>
<td>Doxorubicin (Adriamycin®)</td>
<td>Intravenous (IV)</td>
<td>Used to treat myeloma alone and in combination with other medications</td>
</tr>
<tr>
<td><strong>Antimetabolite</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cytarabine (Cytosine arabinoside,</td>
<td>Intravenous (IV)</td>
<td>Used to treat myeloma</td>
</tr>
<tr>
<td>Ara-C, Cytosar-U®)</td>
<td>Subcutaneous injection</td>
<td></td>
</tr>
</tbody>
</table>
New treatments may have been approved since this booklet was printed. Check www.LLS.org/DrugUpdates or call (800) 955-4572.

### Some Drug Combinations for Myeloma Treatment

- **MP**: melphalan (Alkeran®), prednisone
- **TD**: thalidomide (Thalomid®), dexamethasone
- **RD**: lenalidomide (Revlimid®), dexamethasone
- **Pom/Dex**: pomalidomide (Pomalyst®), dexamethasone
- **VD**: bortezomib (Velcade®), dexamethasone
- **MPT**: melphalan, prednisone, thalidomide
- **VMP**: bortezomib, melphalan, prednisone
- **VTD**: bortezomib, thalidomide, dexamethasone
- **VCD or CyBorD**: bortezomib, cyclophosphamide (Cytoxan®), dexamethasone
- **VRD**: bortezomib, lenalidomide, dexamethasone
- **D-RVD**: Daratumumab (Darzalex®), bortezomib, lenalidomide, dexamethasone
- **CCyD**: carfilzomib (Kyprolis®), cyclophosphamide, dexamethasone
- **KRD**: carfilzomib, lenalidomide, dexamethasone
- **Bortezomib and liposomal doxorubicin (Doxil®)**
- **Carfilzomib, daratumumab, dexamethasone**
- **Carfilzomib, daratumumab and hyaluronidase-fihj (Darzalex Faspro®), dexamethasone**
- **Daratumumab, bortezomib, melphalan, prednisone**
- **Daratumumab, lenalidomide, dexamethasone**
Some Drug Combinations for Myeloma Treatment (continued)

- Daratumumab and hyaluronidase-fihj, pomalidomide, dexamethasone
- Elotuzumab (Empliciti®), lenalidomide, dexamethasone
- Ixazomib (Ninlaro®), lenalidomide, dexamethasone
- Selinexor (Xpovio®), bortezomib, dexamethasone

Stem Cell Transplantation. Some eligible patients may benefit from high-dose chemotherapy followed by a stem cell transplantation. Your healthcare team will talk with you about whether stem cell transplantation is a treatment option for you.

There are two types of stem cell transplantation, one that replaces the patient’s stem cells with his or her own stem cells (autologous transplant), and one that uses replacement stem cells from a donor (allogeneic transplant).

Stem cell transplantation allows doctors to give higher doses of chemotherapy than can typically be given to a patient. Such high doses of chemotherapy can severely damage the stem cells in the bone marrow and result in anemia, serious infections and uncontrolled bleeding. Stem cell transplantation replaces the stem cells destroyed by high-dose chemotherapy.

When doctors are planning treatment, they use a number of factors to determine a patient’s eligibility for stem cell transplantation. These factors may include: the individual’s disease; if the patient is not doing well with other treatments; if the expected benefits of a transplant exceed the risks; if there is a stem cell donor; other treatment(s) received; and physical ability to have the transplant. Stem cell transplantation is not for every patient, but it can be helpful for some.

Additional information about different kinds of transplants is on the following page. Talk to your doctor about whether a stem cell transplant is a possible treatment for you.
Autologous Stem Cell Transplantation. The patient’s own stem cells are collected for this type of stem cell transplantation. If needed, a doctor may use special medications to help mobilize stem cells and move them into the peripheral blood for collection. “Mobilizing” stem cells means stimulating them to move from the bone marrow into the bloodstream so that enough cells can be collected for an autologous transplant. The patient is then treated with high doses of chemotherapy to kill the myeloma cells, but this treatment also kills stem cells in the patient’s bone marrow. To replace the stem cells after chemotherapy, the patient’s stem cells that have been collected and stored are returned to the patient’s bloodstream by an IV infusion (similar to a blood transfusion).

Autologous stem cell transplantation is not a cure for myeloma. It can, however, give patients longer disease-free periods than other standard myeloma therapies. This treatment is not appropriate for all myeloma patients. Patients should discuss the benefits and risks of an autologous stem cell transplantation with their doctors. Myeloma patients who have had an autologous transplant may require maintenance therapy. See Maintenance Therapy on page 30. For patients who are not eligible for an autologous stem cell transplantation, a growing number of treatment choices are available.

Tandem Autologous Stem Cell Transplantation. This is a planned second course of high-dose chemotherapy followed by a second stem cell transplant within 6 months of the first transplant. According to recent studies, this should be considered as a treatment option only in patients who fail to achieve a good response with the first transplant, in select patients with high-risk cytogenetic features, or for patients with plasma cell leukemia.

Allogeneic Stem Cell Transplantation. With allogeneic stem cell transplant, the stem cells are collected from a donor. The donor can be a brother or sister or another person whose stem cells “match” the patient’s. An allogeneic stem cell transplant is a high-risk procedure and has a limited role in myeloma treatment. It should only be done in the context of a clinical trial. Doctors are working to make allogeneic stem cell transplants safer.
Another type of allogeneic stem cell transplant is called a “reduced-intensity transplant” (doctors may also use the term “nonmyeloablative transplant”). This uses lower doses of chemotherapy than a standard allogeneic stem cell transplant. Older and sicker patients may be helped by this treatment.

**WANT MORE INFORMATION?**

You can view, print or order the free LLS publication *Blood and Marrow Stem Cell Transplantation Guide* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for a copy.

**Maintenance Therapy.** Maintenance therapy is treatment that is given to help keep cancer cells suppressed after initial therapy. During maintenance therapy, medications are given at lower doses or less often to keep the successful results of previous treatment going. Maintenance therapy is also given after stem cell transplantation. Lenalidomide (Revlimid®) is FDA-approved for patients with myeloma as maintenance treatment after an autologous stem cell transplantation. Maintenance therapy with bortezomib (Velcade®) or ixazomib (Ninlaro®) is recommended for patients with certain cytogenetic abnormalities. Maintenance therapy is intended to be continued over the long term. Studies continue to explore different drug combinations to be used in maintenance therapy.

**Radiation Therapy.** Radiation therapy uses high-energy rays (x-rays) to kill cancer cells. It may be used to treat patients with a single mass of myeloma (called a *plasmacytoma*), or to treat carefully selected patients whose cancer does not respond to chemotherapy.
Oral Adherence

Many new myeloma drugs are taken orally (by mouth). “Oral adherence” means staying on a set plan by taking your medication in pill form as prescribed—on the right day and at the right time. It is important to make sure that you continue to take your medications at home as prescribed.

There are many benefits of taking a drug by mouth. These include better quality of life and convenience. Unfortunately, when patients do not adhere to their medication plan, their irregular schedule can result in drug resistance, poor response to treatment, progression of disease, increased doctor visits, more lab tests and hospitalizations, and even death.

WANT MORE INFORMATION?

You can view, print or order the free LLS publications Oral Treatment Adherence Facts and A Medication Resource for Blood Cancer Patients at www.LLS.org/booklets, or contact our Information Specialists for copies. You can also view the video Oral Therapies in Myeloma: Medication Adherence at www.LLS.org/videos.

Measuring Treatment Response

Your healthcare team will perform regular tests to see if treatment is working. These test results help decide if changes to treatment are needed.

Blood and urine tests are done to check blood cell counts, kidney function and growth of myeloma cells.

A bone marrow biopsy is used to look at the number and pattern of myeloma cells in the bone marrow.

Imaging tests (x-rays, CT scans, MRIs and PET scans) are used to look at a patient’s bones and bone marrow. X-rays and CT scans are used to see if bones have any holes or breaks, or if there is thinning of the bones. MRIs and PET scans look for changes to the bone marrow and for pockets of myeloma cells.
Some Terms Used to Describe Myeloma Treatment Responses

The doctor may use these terms to talk about a patient’s response to treatment.

**Remission.** No sign of disease; the terms “complete remission” (complete response) or “partial remission” (partial response) are sometimes used.

**Complete response.** No sign of the monoclonal protein (M protein) in the blood and urine. M protein in blood or urine indicates that there is still myeloma in the body.

**Very good partial response.** A 90% or greater decrease in the amount of M protein in the blood.

**Partial response.** A more than a 50 percent decrease in the amount of M protein in the blood; more than a 90 percent decrease in the amount of M protein in the urine over a 24-hour collection time period.

**Stable disease.** Not meeting the criteria to be called a “complete response” or a “very good partial response,” or even a “partial response”; but also not meeting criteria to be called “progressive disease.”

**Progressive disease.** At least a 25 percent increase in the amount of M protein in the blood and urine, new areas of bone damage or a new mass of myeloma cells; progressive disease usually indicates the need to start therapy or change therapies.
Treatment for Relapsed or Refractory Myeloma

After a time, almost all myeloma patients experience relapse, which means the cancer returns after a successful course of treatment. Or the disease may be refractory, which means the cancer does not respond to treatment. In some instances of relapse, the drug or combination of drugs that the patient had a good response to initially may be tried again. Another option for either relapsed or refractory disease is to try a different drug or combination of drugs.

The choice of a treatment regimen after relapse is dependent on a series of factors including:

○ Previous therapy
○ How quickly or slowly the myeloma is progressing
○ Patient health and comorbidities (presence of other health conditions)
○ Genetic abnormalities in the myeloma cells that have developed over time

See Some Drugs Used in Myeloma Treatment on pages 19-26 for options in treating relapsed or refractory myeloma.

PART 3 CLINICAL TRIALS

About Clinical Trials

Doctors may recommend that a patient join a clinical trial. Clinical trials are careful studies done by doctors to test new drugs or treatments. Clinical trials are also used to study new uses for approved drugs or treatments, such as changing the dose of the drug or giving the drug along with another type of treatment or drug. Some clinical trials combine drugs for myeloma in new sequences or dosages.

There are clinical trials for:

○ Newly diagnosed myeloma patients
○ Patients who did not have a good response to treatment (refractory disease)
Patients who relapse after treatment (relapsed disease)
Patients who continue treatment after remission (maintenance therapy)

A carefully conducted clinical trial may provide the best available treatment.

**Here are some questions you may want to ask your healthcare team.** See pages 53-58 for a full list of questions.

1. Is a clinical trial a treatment option?
2. How can I find out if insurance covers the cost of the clinical-trial treatment and treatment-related costs such as testing?
3. Who pays for the travel costs to get to the clinical trial?

Ask your healthcare team if treatment in a clinical trial is right for you. For more information, please call (800) 955-4572 to speak with an LLS Information Specialist who can provide more information about clinical trials. Patients and caregivers can work with **Clinical Trial Nurse Navigators** who will help find clinical trials and personally assist them throughout the entire clinical trial process. Visit the Clinical Trial Support Center at [www.LLS.org/CTSC](http://www.LLS.org/CTSC) for more information.

**WANT MORE INFORMATION?**

You can view, print or order the free LLS publications *Understanding Clinical Trials for Blood Cancers* and *Knowing All Your Treatment Options* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for copies.
Overview of This Section

○ Supportive (palliative) care for myeloma helps patients manage the complications of the disease and the side effects of treatment.

○ After you begin treatment, your healthcare team will regularly order bone marrow tests, lab tests and imaging tests to see how well treatment is working.

○ Myeloma patients should see both their primary care doctor and their cancer specialist regularly for follow-up care.

Complications of Myeloma Therapy

Supportive (palliative) care for myeloma helps patients manage the complications of the disease and the side effects of the drugs used for treatment. The term side effect refers to the way treatment affects healthy cells, but also often describes the negative or undesirable effects of a treatment.

Some complications of myeloma and myeloma therapy include:

**Fatigue.** Fatigue is one of the most common complaints reported by myeloma patients. It may be caused by many factors including anemia, a side effect of both myeloma and its treatment. Sometimes fatigue caused by anemia is treated with drugs that can increase the number of red blood cells in the patient, which may help lessen the severity of anemia.

**Infection.** Myeloma and certain myeloma treatments can increase the risk of infection. Infections are not just troublesome medical problems; they can also contribute to the risk of dying from myeloma.
Patients should follow the doctor’s advice about how to reduce the risk of infection. The doctor may also recommend:

- Intravenous (IV) immunoglobulin therapy, for patients with frequent and life-threatening infections
- Vaccinations for the flu, pneumonia, shingles and COVID-19.
- Treatment to prevent herpes should be considered in patients who are receiving proteasome inhibitors or daratumumab (Darzalex®). These drugs can cause reactivation of the herpes zoster virus (shingles).

**Bone Pain.** Myeloma may cause bone pain due to the thinning and weakening of bones. Acute pain in a bone may even indicate a break or a fracture. Successful treatment of myeloma may relieve bone pain, but some patients may need medication for severe pain. Treatment options for bone pain include drugs called bisphosphonates, which include pamidronate (Aredia®) and zoledronic acid (Zometa®), to help reduce bone pain and the risk of bone fractures. Denosumab (Xgeva®) is FDA-approved to prevent bone fractures in myeloma patients. This medication is recommended when bisphosphonates cannot be used due to potential damage to the kidneys.

**WANT MORE INFORMATION?**

You can view, print or order the free LLS publication *Pain Management* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for a copy.

**Kidney Problems.** Myeloma patients have large amounts of M protein in their urine. They may also have high levels of calcium in their blood. Both M protein in urine and calcium in blood can damage the kidneys. Myeloma treatment can improve kidney function and, in most cases, even return it to normal.

**Myelosuppression.** A condition in which bone marrow activity is decreased, resulting in fewer red blood cells, white blood cells and platelets. Myelosuppression is a side effect of some cancer treatments including chemotherapy agents such as lenalidomide (Revlimid®) and bortezomib (Velcade®). If not managed correctly, myelosuppression can be life-threatening and interfere with treatment planning and quality of life.
Peripheral Neuropathy. This is the term for damage to nerves that causes pain, numbness, tingling or swelling in the arms or legs. It can be caused by the myeloma itself or by certain anticancer drugs. Patients who develop neuropathy should tell their doctors as soon as symptoms appear. Often, reducing the dosage of the drugs or stopping them altogether can alleviate the symptoms.

Thrombosis (DVT). The term “deep vein thrombosis” (abbreviated DVT) refers to a blood clot that forms in a deep vein of the body, usually in a leg. A DVT can cause blood flow obstruction, pain and swelling. Patients who receive myeloma treatments that are associated with DVT risk are usually prescribed medication to reduce the chance of developing a DVT. It is important for patients to discuss this risk with their doctors and ask which of the options to reduce DVT risk is best for them.

Some doctors have observed that taking either thalidomide or lenalidomide and dexamethasone in combination with red blood cell growth factors such as epoetin alpha (Procrit®) or darbepoetin alfa (Aranesp®) further increases a patient’s risk for DVT. Other factors that can increase the risk of DVT include the presence of a central line (central venous catheter), decreased mobility, recent surgery, pregnancy, smoking, a prior history of DVT, or a family history of blood-clotting problems.

Pulmonary Embolism. A pulmonary embolism usually happens when a blood clot breaks loose, travels through the bloodstream and lodges in one or more arteries in the lungs. Depending on the size and number of clots that reach the pulmonary arteries, a patient may experience chest pain, shortness of breath and other potentially severe or even life-threatening symptoms. Certain drugs may increase the risk of developing a pulmonary embolism. The treatments thalidomide (Thalomid®) and lenalidomide (Revlimid®) are associated with an increased incidence of both DVT and pulmonary embolism when they are used in combination with corticosteroids, such as dexamethasone, and in particular, when they are used in combination with liposomal doxorubicin.

WANT MORE INFORMATION?

You can view, print or order the free LLS publications Cancer-Related Fatigue and the Side Effect Management Series (filter for Side Effect Management) at www.LLS.org/booklets, or contact our Information Specialists for copies.
Acute Myeloid Leukemia (AML). Myeloma patients have an increased risk of developing second cancers including acute myeloid leukemia, especially after treatment with certain drugs. This rare complication occurs in a small number of patients.

WANT MORE INFORMATION?

You can view, print or order the free LLS publication *The AML Guide: Information for Patients and Caregivers* at [www.LLS.org/booklets](http://www.LLS.org/booklets), or contact our Information Specialists for a copy.

Chemotherapy Side Effects. Side effects from chemotherapy affect the parts of the body where new cells form quickly. This includes the inside of the mouth and bowel, and the skin and hair. The following side effects are common during chemotherapy:

- Upset stomach and vomiting
- Diarrhea
- Constipation
- Mouth sores
- Hair loss
- Extreme tiredness
- Infections
- Low red blood cell count (anemia)
- Low white blood cell count (neutropenia)
- Low platelet count (thrombocytopenia)
- Achy feeling
- Numb feeling in arms, hands, legs or feet (neuropathy)

Not all patients have these side effects. Talk to your doctor about the possible side effects of your treatment and options to prevent or manage them to feel more comfortable. You can also call our Information Specialists at (800) 955-4572.
Financial Concerns

Myeloma patients are living longer primarily because of the development of new and effective drugs. However, there can be a financial impact because of the cost of these medications.

Speak to your healthcare team if you have any concerns about being able to pay for your medications. A member of your healthcare team may be able to provide information and resources that can help. Health insurance plans may not cover all the costs of cancer care, but there are a number of resources including organizations, foundations and prescription assistance programs available to help patients manage and afford their prescriptions.

In addition, several major pharmaceutical manufacturers (the companies that develop the drugs) provide patient assistance or prescription assistance programs. These companies may be able to help by providing both insured and uninsured patients with either free or reduced-cost medications.

WANT MORE INFORMATION?

You can view, print or order the free LLS booklet Cancer and Your Finances at www.LLS.org/booklets, or contact our Information Specialists for a copy. You can also contact an LLS Information Specialist at (800) 955-4572 for information about the LLS Co-Pay Assistance Program and other financial assistance programs.
Follow-Up Care

Medical follow-up is important for every myeloma patient. Follow-up care helps your healthcare team decide how well your treatment is working and determine if different treatment is needed.

Patients should see their primary care doctors and their hematologist-oncologists (cancer specialists) regularly for follow-up care. Ask your healthcare team how often you will need to have follow-up visits. You should also ask the healthcare team what tests will be needed and find out how often you need to have these tests. It is important to get and keep a record of your cancer treatment, including the drugs you received and the time period you received them, so that your healthcare team can follow up on specific long-term effects that may be associated with your treatment. Page 52 has a space to list your treatments.

Here are some questions you may want to ask your healthcare team. See pages 53-58 for a full list of questions.

1. Who will I work with to ensure life-long follow-up care?
2. Will I continue to see this healthcare team?
3. What information can be given to my primary doctor about past treatment and what may be needed in the future?

Follow-up care may include physical exams, blood tests and urine tests. Sometimes bone marrow tests and imaging tests are also needed.

WANT MORE INFORMATION?

For additional survivorship information, you can view, print or order the free LLS booklet Navigating Life During and After a Blood Cancer Diagnosis at www.LLS.org/booklets, or contact our Information Specialists for copies.
Take Care of Yourself

- Keep all your doctor and lab appointments (specialists, primary care, testing).
- Talk with the healthcare team about how you feel at each visit.
- Ask any questions you may have about side effects.
- People with myeloma may have more infections. Follow your healthcare team’s advice for preventing infection.
- Eat healthy food each day. It may help to eat 4 or 5 smaller meals instead of 3 larger ones.
- Contact your healthcare team if you feel tired, have a fever, or experience other symptoms.
- Do not smoke. Patients who smoke should get help to quit.
- Get enough rest and exercise. Check with your healthcare team before starting an exercise program.
- Keep a healthcare file with copies of lab reports and treatment records.
- Have regular cancer screenings. See your primary care doctor to keep up with your healthcare needs.
- Talk with family and friends about how you feel and about your treatment. When family and friends know about myeloma and its treatment, they may worry less.
- Seek medical advice if you feel sad or depressed and your mood does not improve over time. If you feel sad or depressed every day for a two-week period, seek help. Depression is an illness. It should be treated even when a person is being treated for myeloma. Treatment for depression has benefits for people living with cancer.
RESOURCES AND INFORMATION

LLS offers free information and services for patients and families affected by blood cancers. This section lists various resources you may find helpful.

For Help and Information

Consult with an Information Specialist. Information Specialists can assist you through cancer treatment, financial and social challenges and give accurate, up-to-date disease, treatment and support information. Our Information Specialists are highly trained oncology social workers and nurses. Language services are available. For more information, please:

- Call: (800) 955-4572 (Monday through Friday, 9 a.m. to 9 p.m. ET)
- Email and Live chat: www.LLS.org/InformationSpecialists

Clinical Trials (Research Studies). Research is ongoing to develop new treatment options for patients. LLS offers help for patients and caregivers in understanding, identifying and accessing clinical trials. Pediatric and adult patients and caregivers can work with our Clinical Trial Nurse Navigators who will help find clinical trials and provide personalized support throughout the entire clinical trial process. Visit www.LLS.org/CTSC for more information.

Nutrition Consultations. Schedule a free one-on-one nutrition consultation with one of our registered dietitians who have expertise in oncology nutrition. Consultations are available to patients of all cancer types and their caregivers. Dietitians can assist with information about healthy eating strategies, side effect management and more. Please visit www.LLS.org/nutrition for more information.

Free Information Booklets. LLS offers free education and support booklets for patients, caregivers and healthcare professionals that can either be read online or ordered. Please visit www.LLS.org/booklets for more information.

Telephone/Web Education Programs. LLS offers free telephone/Web and video education programs for patients, caregivers and healthcare professionals. Please visit www.LLS.org/programs for more information.
Financial Assistance. LLS offers financial support to eligible individuals with blood cancer for insurance premiums, co-pays, and non-medical expenses like travel, food, utilities, housing, etc. For more information, please:

- Call: (877) 557-2672
- Visit: www.LLS.org/finances

Podcast. *The Bloodline with LLS* is here to remind you that after a diagnosis comes hope. Listen in as patients, caregivers, advocates, doctors and other healthcare professionals discuss diagnosis, treatment options, quality-of-life concerns, treatment side effects, doctor-patient communication and other important survivorship topics. Visit www.LLS.org/TheBloodline for more information and to subscribe to access exclusive content, submit ideas and topics, and connect with other listeners.

3D Models. LLS offers interactive 3D images to help visualize and better understand blood cell development, intrathecal therapy, leukemia, lymphoma, myeloma, MDS, MPNs, and lab and imaging tests. Visit www.LLS.org/3D for more.

Free Mobile Apps.

- LLS Coloring For Kids™ — Allows children (and adults) to express their creativity and offers activities to help them learn about blood cancer and its treatment. Visit www.LLS.org/ColoringApp to download for free.
- LLS Health Manager™ — Helps you track side effects, medication, food and hydration, questions for your doctor, and more.
  Visit www.LLS.org/HealthManager to download for free.

Suggested Reading. LLS provides a list of selected books recommended for patients, caregivers, children and teens. Visit www.LLS.org/SuggestedReading to find out more.

Connecting with Patients, Caregivers and Community Resources

LLS Community. The one-stop virtual meeting place for talking with other patients and receiving the latest blood cancer resources and information. Share your experiences with other patients and caregivers and get personalized support from trained LLS staff. Visit www.LLS.org/community to join.
Weekly Online Chats. Moderated online chats can provide support and help cancer patients and caregivers reach out and share information. Please visit www.LLS.org/chat for more information.

Local Programs. LLS offers community support and services in the United States and Canada including the Patti Robinson Kaufmann First Connection® Program (a peer-to-peer support program), local support groups and other great resources. For more information about these programs or to contact your region, please:

- Call: (800) 955-4572
- Visit: www.LLS.org/LocalPrograms

Advocacy and Public Policy. Working closely with dedicated volunteer advocates, LLS’s Office of Public Policy elevates the voices of patients to state and federal elected officials, the White House, governors and even courts. Together, we advocate for safe and effective treatments. We pursue policies that would make care more accessible to all patients. And, most of all, we advocate for the hope for a cure. Want to join our work? Visit www.LLS.org/advocacy for more information.

Other Helpful Organizations. LLS offers an extensive list of resources for patients and families. There are resources that provide help with financial assistance, counseling, transportation, patient care and other needs. For more information, please visit www.LLS.org/ResourceDirectory to view the directory.

Additional Help for Specific Populations

Información en Español (LLS information in Spanish). Please visit www.LLS.org/espanol for more information.

Language Services. Let members of your healthcare team know if you need translation or interpreting services because English is not your native language, or if you need other assistance, such as a sign language interpreter. Often these services are free.
Information for Veterans. Veterans who were exposed to Agent Orange while serving in Vietnam may be able to get help from the United States Department of Veterans Affairs. For more information, please

- Call: the VA (800) 749-8387
- Visit: www.publichealth.va.gov/exposures/AgentOrange

Information for Firefighters. Firefighters are at an increased risk of developing cancer. There are steps that firefighters can take to reduce the risk. Please visit www.LLS.org/FireFighters for resources and information.

World Trade Center Health Program. People involved in the aftermath of the 9/11 attacks and subsequently diagnosed with a blood cancer may be able to get help from the World Trade Center (WTC) Health Program. People eligible for help include:

- Responders
- Workers and volunteers who helped with rescue, recovery and cleanup at the WTC-related sites in New York City (NYC)
- Survivors who were in the NYC disaster area and those who lived, worked or were in school in that area
- Responders to the Pentagon and the Shanksville, PA, crashes

For more information, please

- Call: WTC Health Program at (888) 982-4748
- Visit: www.cdc.gov/wtc/faq.html

People Suffering from Depression. Treating depression has benefits for cancer patients. Seek medical advice if your mood does not improve over time, for example, if you feel depressed every day for a 2-week period.

For more information, please:

- Call: The National Institute of Mental Health (NIMH) at (866) 615-6464
- Visit: NIMH at www.nimh.nih.gov and enter “depression” in the search box
Health Terms

**Albumin.** A protein in the blood.

**Anemia.** A condition in which a person has fewer red blood cells than normal.

**Antibody.** A protein made by plasma cells, a type of white blood cell, in response to foreign substances such as bacteria, viruses and fungi. Antibodies help fight infection in the body.

**Bence Jones protein.** An abnormal protein made by myeloma cells. It is found in the urine of most patients with myeloma. It is also called light chains protein.

**Beta\textsubscript{2} microglobulin.** A protein found on the surface of plasma cells and some other cells. A high level of Beta\textsubscript{2} microglobulin may be a sign of faster-growing myeloma.

**Bone lesion.** An area of bone damage or abnormal bone tissue.

**Bone marrow.** The spongy material in the center of bones where blood cells are made.

**Bone marrow aspiration.** A procedure to remove and examine bone marrow cells to see if they are normal. A liquid sample containing cells is taken from the bone marrow, and the cells are looked at under a microscope.

**Bone marrow biopsy.** A procedure to remove and examine bone marrow cells to see if they are normal. A very small amount of bone filled with bone marrow cells is taken from the body, and the cells are looked at under a microscope.

**Chemotherapy or drug therapy.** Treatment that stops the growth of cancer cells, either by killing the cancer cells or stopping them from dividing.
Chromosomes. Threadlike structures within cells that carry genes. Human cells have 23 pairs of chromosomes. The number or shape of chromosomes may be changed in blood cancer cells.

Clinical trial. A careful study done by doctors to test new drugs or treatments or new uses for approved drugs or treatments. The goals of clinical trials for blood cancers are to improve treatment and quality of life and to find cures.

Combination chemotherapy or drug therapy. The use of two or more drugs given together to treat myeloma and other cancers.

FDA. The short name for the US Food and Drug Administration. Part of the FDA’s job is to assure the safety and security of drugs, medical devices and the US food supply.

FISH. The short name for fluorescence in situ hybridization, a test for studying abnormal genes and chromosomes in cells and tissues.

Hematologist. A doctor who specializes in treating blood diseases.

Immune system. A network of cells, tissues and organs in the body that defend the body against infection.

Immunoglobulin. A protein that is made by plasma cells to help fight infections.

Lymphocyte. A type of white blood cell. Some lymphocytes become plasma B cells. Plasma B cells make antibodies to fight infection. Myeloma is a cancer of plasma B cells.

Monoclonal (M) protein. Short for monoclonal immunoglobulin, an abnormal protein made by myeloma cells. The amount of M protein in the blood can be measured. This measure is used to help estimate the seriousness of the myeloma.

Oncologist. A doctor specially trained to treat patients who have cancer.
**Palliative care.** Specialized medical care focused on providing relief from the symptoms and stress of a serious illness. The goal of palliative care is to improve quality of life for both the patient and the family.

**Plasma.** The liquid part of the blood. Blood plasma is not the same as plasma cells or plasma B cells, which are types of white blood cells.

**Plasmacytoma.** A mass made up of abnormal plasma B cells (myeloma cells).

**Platelet.** A type of blood cell that helps stop bleeding. Platelets cause plugs (“clotting”) to form in the blood vessels at the site of an injury.

**Red blood cell.** A type of blood cell that carries oxygen to all parts of the body. In healthy people, red cells make up almost half of the blood.

**Refractory myeloma.** Myeloma that has not responded to initial treatment. Refractory disease may be disease that is getting worse or staying the same (stable disease).

**Relapsed myeloma.** Myeloma that responded to treatment at first but then returns.

**Remission.** A state in which there is no sign of the disease and/or a period of time when the disease is not causing any health problems.

**Smoldering myeloma.** A very slow-growing type of myeloma.

**Stem cell.** A type of cell found in the bone marrow that matures into either a red blood cell, a white blood cell or platelet.

**White blood cell.** A type of blood cell that helps the body fight infection.
MY HEALTHCARE TEAM CONTACT LIST

Use this list to remember names and contact information for members of your healthcare team.

CAREGIVER NAME:

Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: __________________________________________________
Additional information: ___________________________________________

PRIMARY CARE DOCTOR NAME:

Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: __________________________________________________
Additional information: ___________________________________________

PHARMACY NAME:

Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Additional information: ___________________________________________

Information Specialists:
Phone: (800) 955-4572
Email and live chat: www.LLS.org/InformationSpecialists
<table>
<thead>
<tr>
<th>Role</th>
<th>Name</th>
<th>Address</th>
<th>Phone number/Fax number</th>
<th>Email address</th>
<th>Website/Portal</th>
<th>Additional information</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEMATOLOGIST-ONCOLOGIST NAME:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NURSE/NURSE PRACTITIONER NAME:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SOCIAL WORKER NAME:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>INSURANCE CASE MANAGER/CARE COORDINATOR NAME:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PHYSICIAN ASSISTANT NAME:
Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: _________________________________________________
Additional information: _________________________________________

NURSE NAVIGATOR NAME:
Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: _________________________________________________
Additional information: _________________________________________

OTHER
Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: _________________________________________________
Additional information: _________________________________________

OTHER:
Address: ______________________________________________________
Phone number/Fax number: _______________________________________
Email address: _________________________________________________
Additional information: _________________________________________
MY LIST OF TREATMENTS

Use this space to list your treatments and when you took them.

DATE:   _____________________________________________________
Treatment:    _________________________________________________
___________________________________________________________

DATE:   _____________________________________________________
Treatment:    _________________________________________________
__________________________________________________________

DATE:   _____________________________________________________
Treatment:    _________________________________________________
___________________________________________________________

DATE:   _____________________________________________________
Treatment:    _________________________________________________
___________________________________________________________

DATE:   _____________________________________________________
Treatment:    _________________________________________________
___________________________________________________________
QUESTION GUIDE: MY FIRST DOCTOR'S VISIT

Asking questions will help you take an active role in managing your (or your loved one’s) care. If you do not understand any part of the information your healthcare provider gives you, ask them to explain it in another way. The following are questions you may want to ask your healthcare team.

When you meet with the doctor, nurse and healthcare team, ask a few questions to get a better idea of the doctor’s experience and to understand how the office works.

(Note: The use of “I (we)” and “me (us)” in lists of questions is used for situations in which patients may not be old enough or able to make their own decisions. A parent, relative or caregiver may be assisting or making the decisions.)

Questions for the Doctor

DOCTOR’S NAME: ____________________________________________

Date of appointment or phone call: ______________________________

1. How many patients have you treated who have this disease?
2. What problems or symptoms should be reported to the nurse or doctor right away?
3. How long does it normally take to receive a return phone call?
4. How can you be contacted when there are questions?
5. How can you be contacted at night? On weekends? On holidays?
6. Who are the other members of the team that I should be aware of?
7. Is there a release form available so my family/caregiver can be given medical information?
Questions for the Nurse

NURSE OR OTHER HEALTHCARE TEAM MEMBER'S NAME:

___________________________________________________________

1. How long would I (we) have to wait for appointments?

2. What problems or symptoms should be reported to the nurse or doctor right away?

3. How long does it usually take to receive a return phone call?

4. Will there be nurses, social workers and case managers available to help with support needs and quality-of-life concerns?

5. Does your office accept my (our) insurance? Is it considered in-network?

To print copies of other question guides, go to www.LLS.org/WhatToAsk or call (800) 955-4572.
QUESTION GUIDE: Treatment and Follow-Up Care

Talk with the doctor and ask questions about how they plan to treat your (your loved one’s) leukemia. This will help you and your loved one to be actively involved in making decisions about medical care. The following are questions you may want to ask your healthcare team.

(Note: The use of “I (we)” and “me (us)” in lists of questions is used for situations in which patients may not be old enough or able to make their own decisions. A parent, relative or caregiver may be assisting or making the decision.)

DOCTOR’S NAME: ____________________________________________

Date of appointment or phone call: ______________________________

Write down your diagnosis:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________

Write down your stage of myeloma:
_____________________________________________________________________
_____________________________________________________________________
_____________________________________________________________________
Before Treatment Begins

1. Will this treatment affect the ability to have a child in the future?
2. If yes, are there other treatment options available?
3. What are the options for preserving fertility?
4. How much time do I (we) have to make decisions?
5. What is the stage?
6. What is the goal of treatment?
7. What are the treatment options?
8. Are there any clinical trials I could join?
9. When do you think treatment should begin?
10. How long will treatment last?
11. What are the benefits and risks of these treatments?
12. Is there one treatment recommended over the others?
13. How can potential side effects be prevented or managed?

Testing

1. What kind of testing will be done to monitor the disease and treatment?
2. How long does it take to get the results back?
3. How are the results communicated to me (us)?
4. How often will testing be needed?
5. Where will the testing be done?
Treatment

1. Will this be an in-hospital or an outpatient treatment
   - Is it alright to attend work or school during treatment?
   - Will someone be needed to drive me home after treatment?

2. What kind of testing will be done to monitor this disease and treatment?
   How often will testing be needed? Where is the testing done?

3. How will we know if the treatment is effective? What options are available if the treatment is not effective?

4. What is the likely outcome of the disease (prognosis)?

Side Effects

1. What are the common side effects for this treatment?

2. What side effects should be reported to the healthcare team right away?

3. How long will the side effects last?

4. How can potential side effects be prevented or managed?

5. How should I report side effects (phone call, at the office visit, etc)?
Social/Financial Concerns

1. Are there any side effects that will affect appearance or ability to do a job/go to school?

2. What kind of financial and social support services are available to me and my family?

3. How can I (we) find out if insurance will cover the costs of the treatment or the study (clinical trial) treatment?

4. Who is the best person to speak to about bills and insurance coverage?

5. If I (we) do not have insurance coverage, how can the healthcare team help get the treatment needed? Is there someone I can speak to for assistance?

6. If I (we) get in a study treatment (clinical trial), will I (we) be responsible for paying treatment-related costs, such as tests, travel or for clinical-trial drugs?

7. How can I (we) find out if the insurance covers the cost of the clinical trial treatment and treatment-related costs such as testing?

Follow-Up Care and Long-Term and Late Effects

1. Who should I (we) work with to ensure lifelong follow up?

2. Will I (we) continue to see this healthcare team?

3. How can I (we) be monitored for long-term and late effects of treatment?

4. What types of long-term and late effects should be brought to the healthcare team’s attention?

5. If I (we) have side effects later, how can the healthcare team be reached?

6. What information can be provided to a primary doctor about this treatment?

To print copies of other question guides, go to www.LLS.org/WhatToAsk or call (800) 955-4572.
Get support. Reach out to our Information Specialists.

The Leukemia & Lymphoma Society© team consists of highly trained oncology social workers and nurses who are available by phone, email and live chat Monday through Friday, 9 a.m. to 9 p.m. (ET).

- Get one-on-one personalized support and information about blood cancers
- Know the questions to ask your doctor
- Discuss financial resources
- Receive individualized clinical-trial searches
- Get connected to resources

Contact us at 800.955.4572 or www.LLS.org/InformationSpecialists
(Language interpreters can be requested.)
For more information, please contact our Information Specialists 800.955.4572 (Language interpreters available upon request).

National Office  3 International Drive, Suite 200  Rye Brook, NY 10573

The mission of The Leukemia & Lymphoma Society (LLS) is to cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. Find out more at www.LLS.org.